CAR T cell therapy for refractory pediatric systemic lupus erythematosus: a new era of hope?

ABSTRACT: Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can affect multiple organ systems and is heterogenous in its presentation and response to therapy. When diagnosed in childhood, SLE is associated with increased morbidity and mortality compared to adult SLE, often requiring substantial immunosuppression with the risk of significant side effects. There remains a significant unmet need for new therapies that can improve disease control and reduce glucocorticoid and other toxic medication exposure for patients with severe or refractory disease. The pathogenesis of SLE involves B cell dysregulation and autoantibody production, which are a hallmark of the disease. Currently approved B cell directed therapies often result in incomplete B cell depletion and may not target l

SUBMITTER: Stojkic I 

PROVIDER: S-EPMC11308704 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature